Giulia C. Kennedy - Jun 23, 2021 Form 4 Insider Report for VERACYTE, INC. (VCYT)

Role
Chief Scientific & Med Officer
Signature
/s/ Jane Alley as attorney-in-fact
Stock symbol
VCYT
Transactions as of
Jun 23, 2021
Transactions value $
-$65,895
Form type
4
Date filed
6/25/2021, 04:12 PM
Previous filing
Jun 8, 2021
Next filing
Sep 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCYT Common Stock Options Exercise $108K +4.38K +8.43% $24.69 56.3K Jun 23, 2021 Direct F1
transaction VCYT Common Stock Sale -$174K -4.38K -7.78% $39.75 51.9K Jun 23, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VCYT Stock Option (right to buy) Options Exercise $0 -4.38K -8.33% $0.00 48.1K Jun 23, 2021 Common Stock 4.38K $24.69 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020.
F2 Represents weighted average sales price. Sale prices for the transactions range from $39.69 to $39.84. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
F3 The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.